增持完成公告 证券代码：301033 证券简称：迈普医学 公告编号：2024-036 广州迈普再生医学科技股份有限公司 关于公司部分董事、高级管理人员自愿增持公司股份计划 实施完成的公告 特别提示 1、增持计划的基本情况：广州迈普再生医学科技股份有限公司 （以下简称"公司"）董事、总经理王建华先生拟自本次增持计划公 告披露之日起 6 个月内（即 2024 年 2 月 7 日至 2024 年 8 月 6 日，除 法律、法规及有关规定不得增持的期间外）通过深圳证券交易所交易 系统以集中竞价的方式增持公司股份，拟增持金额为人民币 25 万元 -50 万元。具体内容详见公司于 2024 年 2 月 7 日在巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于公司实际控制人、控股 股东和部分董事、高级管理人员自愿增持公司股份计划的公告》。 2、增持计划的实施情况：截至本公告披露日，公司董事、总经 理王建华先生已通过深圳证券交易所交易系统以集中竞价方式累计 增持公司股份 7,600 股，占公司总股本（已剔除回购专户中股份数量， 下同）的 0.01%，增持金额为人民币 250,312 元（不包含交易 ...

Summary of the Conference Call for Maipu Medical Company Overview - Maipu Medical was established in 2008, focusing on medical printing and developing high-value consumables for neurosurgery [3][4] - The company has expanded its product line to include various neurosurgical repair solutions, including hemostatic materials and membranes [4][6] Key Products and Developments 1. **Membrane Products** - The company has two main membrane products: Ruimo and Ruikang, designed for endoscopic surgeries [5] - The first membrane product received EU registration in 2011 and entered the Chinese market in 2014, capturing approximately 10% of the domestic market [6][8] 2. **PEK Repair System** - The PEK system is positioned as a superior alternative to titanium metal for repairing bone defects, addressing issues such as thermal expansion and imaging interference [11][12] - Currently, PEK accounts for less than 15% of the market, indicating significant potential for growth and market penetration [12][13] 3. **Hemostatic Gauze** - The hemostatic gauze, made from regenerated cellulose, aims to break the monopoly of Johnson & Johnson in the domestic market [16][17] - The product is currently limited to neurosurgery but is expected to expand into general surgery, with clinical trials ongoing [18][20] 4. **Dural Glue** - The dural glue product is designed to prevent cerebrospinal fluid leakage post-surgery, addressing a significant clinical need [21][22] - The product received registration in February 2023 and is in the promotion phase [25] Market Dynamics - The company is actively participating in centralized procurement across multiple provinces, with significant progress in provinces like Jiangsu, Shandong, and Henan [8][10] - The ongoing centralized procurement is expected to enhance market share and pricing competitiveness [10][15] Financial Performance - Revenue growth for 2022 was reported at 18.24%, with a first-quarter growth of 28.59% in 2023, driven by product line expansion and brand strength [29][30] - The company has maintained a 30%+ growth rate in overseas markets, selling products in over 90 countries [30] Competitive Landscape - The domestic market for high-value consumables in neurosurgery is competitive, with several local manufacturers emerging [28][45] - Maipu Medical differentiates itself through the use of synthetic materials, avoiding animal-derived components, which enhances its appeal in both domestic and international markets [46][48] Future Outlook - The company aims to increase its market share in neurosurgery to 20% over the next few years, leveraging its competitive pricing and product advantages [32][33] - Continued focus on product innovation and expanding into new surgical areas is expected to drive future growth [35][36] Additional Insights - The company is optimistic about the potential for PEK to replace titanium in the market, especially as awareness of its advantages grows [39][40] - The hemostatic gauze is positioned to meet the increasing demand for high-performance surgical materials, with expectations of further market penetration [61][62] This summary encapsulates the key points discussed during the conference call, highlighting Maipu Medical's strategic initiatives, product offerings, market dynamics, and future growth prospects.

Group 1: Company Overview - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. focuses on developing high-performance implantable medical devices using advanced manufacturing technology and synthetic materials [2] - The company is the only domestic enterprise in the neurosurgery field that offers a range of products including artificial dura mater patches and absorbable regenerated oxidized cellulose [2] Group 2: Financial Performance - In 2023, the company achieved a total revenue of 23,086.97 million CNY, with a net profit attributable to shareholders of 4,087.74 million CNY, marking a year-on-year growth of 13.89% [3] - The sales revenue for artificial dura mater patches reached 13,959.91 million CNY, accounting for 60.47% of total revenue, while the craniofacial repair and fixation system generated 6,096.67 million CNY, representing 26.41% [3] - In Q1 2024, the company reported a revenue of 5,720.61 million CNY, a year-on-year increase of 28.59%, with a net profit of 1,207.26 million CNY, up 91.19% [3] Group 3: Product Development and Market Position - The second-generation dura mater patch "Rui Mo®" was first registered in 2011 and is the only product in the 2018 Ministry of Science and Technology's list of innovative medical devices [3] - PEEK materials are becoming the preferred choice over titanium in craniofacial repair due to their superior properties, and the company is among the few in China utilizing PEEK in its products [4] - The company is actively working on expanding the indications for its absorbable regenerated oxidized cellulose hemostatic products, which currently face little domestic competition [5] Group 4: Future Strategies - The company plans to optimize its sales team structure and capabilities in response to market penetration and product diversification, aiming to provide specialized services to end customers [5]

内部控制自我评价报告的核查意见 华泰联合证券有限责任公司 关于广州迈普再生医学科技股份有限公司 2023年度内部控制自我评价报告的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"）作为广州迈普再生医学科 技股份有限公司（以下简称"迈普医学"、"公司"或"发行人"）首次公开发行股 票并在创业板上市的保荐人，根据《证券发行上市保荐业务管理办法》、《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等文件的要求， 华泰联合对迈普医学 2023 年度内部控制制度等相关事项进行核查，并发表独立意见如 下： 一、内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高风险领 域。 纳入评价范围的主要单位包括公司及子公司，及其各事业部和职能部门，纳入评 价范围单位资产总额占公司合并财务报表资产总额的 100%，营业收入合计占公司合并 财务报表营业收入总额的 100%。 纳入评价范围的主要业务和事项包括；组织结构、内部审计、资金活动、募集资 金使用和管理、发展战略、人力资源、公司文化建设等；重点关注的高风险领域主要 包括：风险管理机制、采购业务、销售业务、固定资产内部 ...

年度持续督导跟踪报告 华泰联合证券有限责任公司关于 广州迈普再生医学科技股份有限公司 2023 年度持续督导跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：迈普医学 | | --- | --- | | 保荐代表人姓名：刘恺 | 联系电话：0755-82492010 | | 保荐代表人姓名：张冠峰 | 联系电话：0755-82492010 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 0 次，募集资金专户已于 2021 年注销 | | ...

Investment Rating - The report gives a "Buy" rating for the company, indicating an expected investment return exceeding 15% over the next 6-12 months [67]. Core Insights - The company has a strong position in the neurosurgery market, particularly in artificial dura mater products, which have completed import substitution. Other segments still see foreign products dominating [34][75]. - The company is experiencing rapid growth in its craniofacial repair products, with a significant increase in revenue and market share due to successful bidding in provincial procurement [78]. - The report highlights the potential for the company's high-performance hemostatic products to capture market share from competitors like Johnson & Johnson [45]. Company Overview - The company operates in three main business segments within the neurosurgery field: artificial dura mater, craniofacial repair products, and hemostatic products [3][5]. - The primary revenue source is the artificial dura mater, which accounted for over 70% of revenue from 2017 to 2022, but has decreased to 60% in 2023 due to national procurement policies [5]. - The company has seen a rapid increase in craniofacial repair product sales, with a 60% year-on-year growth in 2023, raising its revenue share to 26.4% [5]. Market Dynamics - The neurosurgery high-value consumables market is experiencing strong demand, with high-performance products expected to capture more market share [6]. - The artificial dura mater market in China is approximately 1 billion yuan, with a high degree of domestic substitution achieved [8]. - The craniofacial repair product market is projected to grow significantly, driven by increasing incidences of related medical conditions and advancements in materials like PEEK [13][39]. Financial Performance - The company’s domestic revenue accounts for over 78%, while international markets are growing rapidly, with a compound annual growth rate of 40% from 2019 to 2023 [5]. - Revenue projections for 2024-2026 indicate expected growth rates of 21.3%, 28.9%, and 31.7%, respectively, with net profit growth rates of 35.2%, 54.2%, and 52.9% [67][69]. Product Development - The company has a rich pipeline of products under development, including absorbable hemostatic materials and oral repair membranes, which are expected to enhance its competitive edge in the industry [62][88]. - The report emphasizes the company's innovative use of PEEK materials in craniofacial repair products, which offer significant advantages over traditional titanium materials [39][79].

北京市中伦（广州）律师事务所 关于广州迈普再生医学科技股份有限公司 2023 年年度股东大会的 法律意见书 二〇二四年五月 广东省广州市天河区珠江新城华夏路 10 号富力中心 23 楼整层及 31 楼 01、04 单元 邮编：510623 23/F, Units 01 & 04 of 31/F, R&F Center, 10 Huaxia Road, Zhujiang New Town, Tianhe District Guangzhou, Guangdong 510623, P. R. China 电话/Tel : +86 20 2826 1688 传真/Fax : +86 20 2826 1666 www.zhonglun.com 北京市中伦（广州）律师事务所 关于广州迈普再生医学科技股份有限公司 2023 年年度股东大会的 法律意见书 致：广州迈普再生医学科技股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）接受广州迈普再生医学 科技股份有限公司（以下简称"公司"）委托，指派孙巧芬和曾思律师（以下简称 "本所律师"）对公司 2023 年年度股东大会（以下简称"本次股东大会"）的合法 性进行见 ...

证券代码：301033 证券简称：迈普医学 公告编号：2024-030 广州迈普再生医学科技股份有限公司 关于换届选举第三届监事会职工代表监事的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 选举职工代表监事公告 公司 2024 年第一次职工代表大会决议。 选举职工代表监事公告 特此公告。 广州迈普再生医学科技股份有限公司 一、第三届监事会职工代表监事选举情况 广州迈普再生医学科技股份有限公司（以下简称"公司"、"迈 普医学"）第二届监事会任期将于 2024 年 6 月 15 日届满，根据《公 司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、 行政法规、规范性文件及《公司章程》的有关规定，结合公司目前监 事会构成及任职情况，为适应公司现阶段业务经营及未来发展的实际 需求，公司于 2024 年 5 月 10 日在公司会议室召开 2024 年第一次职 工代表大会，经全体与会职工代表审议，一致同意选举彭柳思女士为 公司第三届监事会职工代表监事（简历见附件）。彭柳思女士将与公 司 20 ...

总经理工作细则 MP-CG-009,V2.0 广州迈普再生医学科技股份有限公司 总经理工作细则 二〇二四年五月 总经理工作细则 MP-CG-009,V2.0 第一章 总则 第一条 为了促进公司经营管理的制度化、规范化、科学化，确保公司重大经营决策的正 确性、合理性，提高民主决策、科学决策水平，依据《中华人民共和国公司法》（以下简称： "《公司法》"）和《广州迈普再生医学科技股份有限公司章程》（以下简称："《公司章程》"）， 特制定本工作细则。 第二条 公司的总经理及其他有关高级管理人员的产生、任职资格、履行职权等除应遵守 本细则的规定外，还应符合相关法律、法规、规范性文件和《公司章程》的规定。 第二章 任免程序及任职资格 第三条 公司设总经理一名，副总经理若干名，由董事会聘任或解聘。总经理主持公司日 常生产经营和管理工作，组织实施本公司董事会决议，对董事会负责。非独立董事可受聘兼任 总经理、副总经理或者其他高级管理人员，但兼任总经理、副总经理或者其他高级管理人员职 务的董事不得超过公司董事总数的二分之一。 第四条 公司总经理由董事长提名，董事会聘任；副总经理由总经理提名，董事会聘任； 任何组织和个人不得干预公 ...

董事会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2024-032 广州迈普再生医学科技股份有限公司 第三届董事会第一次会议决议公告 一、董事会会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）第三 届董事会第一次会议于 2024 年 5 月 10 日下午 16:30 在公司会议室以 现场和通讯方式召开。为了保障公司董事会顺利运行，公司在 2023 年年度股东大会选举产生第三届董事会成员即日召开第三届董事会 第一次会议。根据《公司章程》《董事会议事规则》的相关规定，并 经全体董事同意，豁免本次会议通知的时间要求。会议通知已于 2024 年 5 月 10 日通过现场口头及通讯方式传达。经全体董事共同推选， 本次会议由董事袁玉宇先生召集并主持，公司全体董事出席了会议， 全体监事、高级管理人员列席了会议。会议应出席董事 9 人，实际出 席董事 9 人，其中，袁美福先生、郑海莹女士以通讯方式出席会议。 本次会议的召集、召开和表决程序符合国家有关法律、行政法规及《广 州迈普再生医学科技股份有限公司章程》（以下简称"《公司章程》"） 的规定，会议形成的决议合法有效。 二、董事会会议审议 ...